These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
980 related articles for article (PubMed ID: 26121236)
1. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. Craig VJ; Zhang L; Hagood JS; Owen CA Am J Respir Cell Mol Biol; 2015 Nov; 53(5):585-600. PubMed ID: 26121236 [TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis. Mahalanobish S; Saha S; Dutta S; Sil PC Pharmacol Res; 2020 Feb; 152():104591. PubMed ID: 31837390 [TBL] [Abstract][Full Text] [Related]
3. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. Todd JL; Vinisko R; Liu Y; Neely ML; Overton R; Flaherty KR; Noth I; Newby LK; Lasky JA; Olman MA; Hesslinger C; Leonard TB; Palmer SM; Belperio JA; BMC Pulm Med; 2020 Mar; 20(1):64. PubMed ID: 32171287 [TBL] [Abstract][Full Text] [Related]
4. Pivotal role of matrix metalloproteinase 13 in extracellular matrix turnover in idiopathic pulmonary fibrosis. Nkyimbeng T; Ruppert C; Shiomi T; Dahal B; Lang G; Seeger W; Okada Y; D'Armiento J; Günther A PLoS One; 2013; 8(9):e73279. PubMed ID: 24023851 [TBL] [Abstract][Full Text] [Related]
5. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Pardo A; Cabrera S; Maldonado M; Selman M Respir Res; 2016 Mar; 17():23. PubMed ID: 26944412 [TBL] [Abstract][Full Text] [Related]
6. MMP expression and abnormal lung permeability are important determinants of outcome in IPF. McKeown S; Richter AG; O'Kane C; McAuley DF; Thickett DR Eur Respir J; 2009 Jan; 33(1):77-84. PubMed ID: 18829682 [TBL] [Abstract][Full Text] [Related]
7. Upregulation and Nuclear Location of MMP28 in Alveolar Epithelium of Idiopathic Pulmonary Fibrosis. Maldonado M; Salgado-Aguayo A; Herrera I; Cabrera S; Ortíz-Quintero B; Staab-Weijnitz CA; Eickelberg O; Ramírez R; Manicone AM; Selman M; Pardo A Am J Respir Cell Mol Biol; 2018 Jul; 59(1):77-86. PubMed ID: 29373068 [TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase-19 is a key regulator of lung fibrosis in mice and humans. Yu G; Kovkarova-Naumovski E; Jara P; Parwani A; Kass D; Ruiz V; Lopez-Otín C; Rosas IO; Gibson KF; Cabrera S; Ramírez R; Yousem SA; Richards TJ; Chensny LJ; Selman M; Kaminski N; Pardo A Am J Respir Crit Care Med; 2012 Oct; 186(8):752-62. PubMed ID: 22859522 [TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives. Yue L; Shi Y; Su X; Ouyang L; Wang G; Ye T Eur J Med Chem; 2021 Nov; 224():113714. PubMed ID: 34315043 [TBL] [Abstract][Full Text] [Related]
10. Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis. Fujishima S; Shiomi T; Yamashita S; Yogo Y; Nakano Y; Inoue T; Nakamura M; Tasaka S; Hasegawa N; Aikawa N; Ishizaka A; Okada Y Arch Pathol Lab Med; 2010 Aug; 134(8):1136-42. PubMed ID: 20670133 [TBL] [Abstract][Full Text] [Related]
11. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Knipe RS; Tager AM; Liao JK Pharmacol Rev; 2015; 67(1):103-17. PubMed ID: 25395505 [TBL] [Abstract][Full Text] [Related]
16. Loss of MT1-MMP in Alveolar Epithelial Cells Exacerbates Pulmonary Fibrosis. Placido L; Romero Y; Maldonado M; Toscano-Marquez F; Ramírez R; Calyeca J; Mora AL; Selman M; Pardo A Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805743 [TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. Ghebremariam YT; Cooke JP; Gerhart W; Griego C; Brower JB; Doyle-Eisele M; Moeller BC; Zhou Q; Ho L; de Andrade J; Raghu G; Peterson L; Rivera A; Rosen GD J Transl Med; 2015 Aug; 13():249. PubMed ID: 26231702 [TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Yamashita CM; Dolgonos L; Zemans RL; Young SK; Robertson J; Briones N; Suzuki T; Campbell MN; Gauldie J; Radisky DC; Riches DW; Yu G; Kaminski N; McCulloch CA; Downey GP Am J Pathol; 2011 Oct; 179(4):1733-45. PubMed ID: 21871427 [TBL] [Abstract][Full Text] [Related]
19. Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-β receptor I internalization and inhibiting transforming growth factor-β1 signaling. Shi Y; Gochuico BR; Yu G; Tang X; Osorio JC; Fernandez IE; Risquez CF; Patel AS; Shi Y; Wathelet MG; Goodwin AJ; Haspel JA; Ryter SW; Billings EM; Kaminski N; Morse D; Rosas IO Am J Respir Crit Care Med; 2013 Oct; 188(7):831-41. PubMed ID: 23924348 [TBL] [Abstract][Full Text] [Related]
20. A Tale of Two Proteolytic Machines: Matrix Metalloproteinases and the Ubiquitin-Proteasome System in Pulmonary Fibrosis. Roque W; Boni A; Martinez-Manzano J; Romero F Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485920 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]